6937-03-7

Basic information

• Product Name: Methyl 2-aminopyridine-4-carboxylate
• Synonyms: METHYL 2-AMINOISONICOTINATE;METHYL 2-AMINOPYRIDINE-4-CARBOXYLATE;CHEMBRDG-BB 4015127;2-Aminopyridinecarboxylic acid methyl ester~Methyl 2-aminoisonicotinate;2-Aminopyridine-4-carboxylic acid methyl ester;2-aminopyridinecarboxylic acid methyl ester;methyl 2-aminoisonicotinate, (2-Amino-4-pyridinecarboxylic acid methylester);Methyl 2-Amino-4-pyridinecarboxylate
• CAS NO: 6937-03-7
• Molecular Formula: C₇H₈N₂O₂
• Molecular Weight: 152.15
• EINECS: -0
• Product Categories: Esters;Pyridines;Pyridine;API intermediates;Amines;Heterocycles;Inhibitors;Heterocycle-Pyridine series
• Mol File: 6937-03-7.mol

Chemical Properties

• Melting Point: 146-148°C
• Boiling Point: 296.1 °C at 760 mmHg
• Flash Point: 132.9 °C
• Appearance: White to brown/Crystalline Powder
• Density: 1.238 g/cm³
• Vapor Pressure: 0.00146mmHg at 25°C
• Refractive Index: 1.57
• Storage Temp.: Refrigerator
• Solubility: Chloroform
• PKA: 4.89±0.11(Predicted)
• Water Solubility: Insoluble in water.
• BRN: 128642
• CAS DataBase Reference: Methyl 2-aminopyridine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-aminopyridine-4-carboxylate(6937-03-7)
• EPA Substance Registry System: Methyl 2-aminopyridine-4-carboxylate(6937-03-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-41-20/22
• Safety Statements: 26-36-26/36-39-36/37/39-22
• HazardClass: IRRITANT
• Hazardous Substances Data: 6937-03-7(Hazardous Substances Data)

Usage

Uses

1. Used in Pharmaceutical Industry:
Methyl 2-aminopyridine-4-carboxylate is used as a nitrogen monoxide synthetase inhibitor for its potential therapeutic applications in treating conditions related to the overproduction of nitrogen monoxide, which can contribute to inflammation and other health issues.
2. Used in Research and Development:
Methyl 2-aminopyridine-4-carboxylate serves as a valuable compound in the field of research and development, particularly in the study of nitrogen monoxide synthetase and its role in various biological processes. Its inhibitory properties make it a useful tool for understanding the enzyme's function and for developing new drugs targeting this enzyme.

InChI:InChI=1/C7H8N2O2/c1-11-7(10)5-2-3-9-6(8)4-5/h2-4H,1H3,(H2,8,9)

Upstream product

• 26218-82-6 2-Nitro-isonicotinsaeure-methylester 
• 54221-95-3 2-(acetylamino)isonicotinic acid 
• 67-56-1 methanol 
• 13362-28-2 2-aminoisonicotinic acid 
• 107-20-0 2-chloroethanal 
• 882499-87-8 methyl 2-amino-5-bromo-pyridine-4-carboxylate 
• 3783-38-8 methyl isonicotinate N-oxide 
• 5327-32-2 2-acetylamino-4-methylpyridine 
• 33225-74-0 2-nitropyridine-4-carboxylic acid 
• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 
• 695-34-1 2-Amino-4-methylpyridine 
• 58481-11-1 methyl 2-chloroisonicotinate 
• 89937-77-9 methyl 2-hydroxypyridine-4-carboxylate 
• 1210824-89-7 2-amino-isonicotinic acid methyl ester hydrochloride 

Downstream Products

• 98953-21-0 methyl 2-acetamidoisonicotinate 
• 13538-42-6 2-amino-isonicotinamide 
• 128616-96-6 2-<2-(3-benzyloxy-4-nitrophenyl)vinyl>-7-methoxycarbonyl-3-methylimidazo<1,2-a>pyridine 
• 86718-01-6 methyl 7-imidazo<1,2-a>pyridinecarboxylate 
• 97524-44-2 N¹-[2-(4-acetylsulfanilamido)]-4-methoxycarbonylpyridine 
• 58481-01-9 2-aminoisonicotinic acid hydrazide 
• 952206-61-0 6-(2,4-dichloro-phenyl)-imidazo[1,2-a]pyridine-7-carboxylic acid methyl ester 
• 128617-11-8 2-<2-(4-amino-3-hydroxyphenyl)ethyl>-7-hydroxymethyl-3-methylimidazo<1,2-a>pyridine 
• 128617-02-7 2-<2-(4-amino-3-hydroxyphenyl)ethyl>-7-methoxycarbonyl-3-methylimidazo<1,2-a>pyridine 
• 105250-17-7 2-amino-4-hydroxymethylpyridine 
• 882499-87-8 methyl 2-amino-5-bromo-pyridine-4-carboxylate 
• 212322-45-7 3-Methyl-2-[2-(4-cyanophenyl)ethyl]-imidazo[1.2-a]pyridin-7-yl-carboxylicacid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide 
• 937055-00-0 methyl 2-({3-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]propanoyl}amino)isonicotinate 
• 1247733-95-4 C₁₄H₁₁N₃O₆ 

Relevant articles and documents

2-aminopyridine-4-methyl formate synthesizing method

The invention discloses a 2-aminopyridine-4-methyl formate synthesizing method which comprises the following steps: firstly, preparing a Fe-Mn-Mo-TiO catalyst; then mixing 2-amino-4-methyl pyridine with water; heating to 40 to 50 DEG C; adding a Fe-Mn-Mo-TiO catalyst; stirring; dropwise adding dilute nitric acid; stirring and reacting for 3 to 4h; cooling to room temperature; filtering; adjustinga pH of filtrate as 9 to 10; then adding methyl alcohol; heating, refluxing and reacting for 1 to 2h; performing reduced pressure distillation to remove the methyl alcohol; utilizing dichloromethane to perform repeated extraction; combining organic phases; performing reduced pressure distillation to remove the dichloromethane; obtaining the 2-aminopyridine-4-methyl formate. The synthesizing methoddisclosed by the invention has the advantages of simpleness in operation, moderate condition, smaller byproducts, high product purity and higher product yield.

Spin-Center Shift-Enabled Direct Enantioselective α-Benzylation of Aldehydes with Alcohols

Nature routinely engages alcohols as leaving groups, as DNA biosynthesis relies on the removal of water from ribonucleoside diphosphates by a radical-mediated "spin-center shift" (SCS) mechanism. Alcohols, however, remain underused as alkylating agents in synthetic chemistry due to their low reactivity in two-electron pathways. We report herein an enantioselective α-benzylation of aldehydes using alcohols as alkylating agents based on the mechanistic principle of spin-center shift. This strategy harnesses the dual activation modes of photoredox and organocatalysis, engaging the alcohol by SCS and capturing the resulting benzylic radical with a catalytically generated enamine. Mechanistic studies provide evidence for SCS as a key elementary step, identify the origins of competing reactions, and enable improvements in chemoselectivity by rational photocatalyst design.

AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF

The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.

NOVEL COMPOUND, ORGANIC CATION TRANSPORTER 3 DETECTION AGENT, AND ORGANIC CATION TRANSPORTER 3 ACTIVITY INHIBITOR

[Problem] The present invention addresses the problem of providing a novel compound. The present invention also addresses the problem of providing an OCT3 detection agent or an OCT3 activity inhibitor, which comprises the novel compound. [Solution] A compound represented by formula (A), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. ????????R1-R2-R3-R4?????(A)

Structure-based optimization of oxadiazole-based GSK-3 inhibitors

Inhibition of glycogen synthase kinase-3 (GSK-3) induces neuroprotective effects, e.g. decreases β-amyloid production and reduces tau hyperphosphorylation, which are both associated with Alzheimer's disease (AD). The two isoforms of GSK-3 in mammalians are GSK-3α and β, which share 98% homology in their catalytic domains. We investigated GSK-3 inhibitors based on 2 different scaffolds in order to elucidate the demands of the ATP-binding pocket [1]. Particularly, the oxadiazole scaffold provided potent and selective GSK-3 inhibitors. For example, the most potent inhibitor of the present series, the acetamide 26d, is characterized by an IC50 of 2 nM for GSK-3α and 17 nM for GSK-3β. In addition, the benzodioxane 8g showed up to 27-fold selectivity for GSK-3α over GSK-3β, with an IC 50 of 35 nM for GSK-3α. Two GSK-3 inhibitors were further profiled for efficacy and toxicity in the wild-type (wt) zebrafish embryo assay to evaluate simultaneously permeability and safety.

Second-generation supramolecular dendrimer with a defined structure due to orthogonal binding

A second-generation supramolecular dendrimer has been prepared by orthogonal multiple hydrogen bonding. In the first (inner) recognition domain, the interaction of one bis-isocyanuric acid (25) with two branching units (21) that carry complementary Hamilt

Synthesis, biological evaluation and molecular docking studies of novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone derivatives

In present study, a series of new 2-(1,3,4-oxadiazol-2-ylthio)-1- phenylethanone derivatives (6a-6x) as potential focal adhesion kinase (FAK) inhibitors were synthesized. The bioassay assays demonstrated that compound 6i showed the most potent activity, which inhibited the growth of MCF-7 and A431 cell lines with IC50 values of 140 ± 10 nM and 10 ± 1 nM, respectively. Compound 6i also exhibited significant FAK inhibitory activity (IC50 = 20 ± 1 nM). Docking simulation was performed to position compound 6i into the active site of FAK to determine the probable binding model.

Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active site 'capping' phenyls

Nitrogen-containing bisphosphonates (N-BPs) are potent active site inhibitors of the human farnesyl pyrophosphate synthase (hFPPS) and valuable human therapeutics for the treatment of bone-related malignancies. N-BPs are also useful in combination chemotherapy for patients with breast, prostate and multiple myeloma cancers. A structure-based approach was employed in order to design inhibitors that exhibit higher lipophilicity and better occupancy for the GPP sub-pocket of hFPPS than the current therapeutic drugs. These novel analogs were designed to bind deeper into the GPP sub-pocket by displacing the side chains of the 'capping' residue Phe 113 and engaging in favorable π-interactions with the side chain of Phe112.

IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES

The present invention relates to imidazopyridine and imidazopyrimidine derivatives that act as cannabinoid receptor ligands, e.g., CB2 ligands. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.